BA
REGN icon

Bridgewater Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Bridgewater Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$225K Sell
319
-3
-0.9% -$2.3K 0.01% 418
2025
Q4 		$237K Buy
+322
New +$219K 0.02% 410

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bridgewater Advisors's REGN Position: Q1 2026 in Review

Bridgewater Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 0.93% in Q1 2026, selling an estimated $2.3K and leaving 319 shares worth $225K. The position accounts for 0.01% of the portfolio, ranked #418.

Bridgewater Advisors first reported a position in REGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $237K in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Bridgewater Advisors held 319 shares of Regeneron Pharmaceuticals worth $225K as of Q1 2026.
  • Bridgewater Advisors sold 3 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $2.3K.
  • Regeneron Pharmaceuticals made up 0.01% of Bridgewater Advisors's portfolio in Q1 2026, its #418 holding.
  • Bridgewater Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • Bridgewater Advisors's Regeneron Pharmaceuticals position peaked at $237K in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Bridgewater Advisors's 13F filing for Q1 2026, filed 14 May 2026.